Form 4: Adaptive Biotechnologies CEO Sells Shares for Tax Cover

Adaptive Biotechnologies CEO Chad M. Robins sold 470,167 shares of common stock for $6.19 million to cover tax obligations from RSU and PSU vesting.

Summary

• Chad M. Robins, CEO and Chairman of Adaptive Biotechnologies Corp (ADPT), disposed of a total of 470,167 shares of common stock.
• The sales occurred on March 11, 2026, at a price of $13.17 per share.
• The total value of the shares sold was approximately $6,192,900.39.
• These transactions were non-discretionary 'sell to cover' sales, mandated by the Issuer's equity incentive plans to satisfy tax withholding obligations related to the vesting of Restricted Stock Units (RSUs) and Performance Share Units (PSUs).
• Following these transactions, Mr. Robins directly beneficially owns 2,301,113 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While a large insider sale could be concerning, the explicit explanation that it's a non-discretionary 'sell to cover' for tax purposes mitigates any negative sentiment regarding management's confidence.

Positives

• The vesting of Restricted Stock Units (RSUs) and Performance Share Units (PSUs) indicates that performance conditions, if any, were met, and the executive is realizing value from their equity compensation.

Negatives

• A significant number of shares (470,167) were sold by a key insider, which, if not for the 'sell to cover' explanation, could be perceived negatively by the market.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The sales were mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a 'sell to cover' transaction.
• The sales do not represent a discretionary trade by the Reporting Person.

Industry Context

StockSavvy.ai notes that 'sell to cover' transactions are a common and routine occurrence for executives in the biotechnology and broader corporate sectors when equity awards like RSUs and PSUs vest. These sales are typically not indicative of an executive's sentiment towards the company's future prospects but rather a mechanism to manage tax liabilities associated with compensation.

Comparison to Industry Standards

• The practice of 'sell to cover' for tax obligations upon equity vesting is a standard mechanism across publicly traded companies, particularly in high-growth sectors like biotechnology, to manage executive compensation and tax liabilities.
• Similar transactions are routinely observed in companies like Illumina (ILMN) or Guardant Health (GH) where executives receive substantial equity compensation.

Related Party Transactions

• The transactions involve the sale of shares by the CEO to cover tax obligations arising from equity awards granted by Adaptive Biotechnologies Corporation, which is a form of related party dealing inherent in executive compensation structures.

Stakeholder Impact

• Shareholders: The sale increases the float of shares, but the non-discretionary nature means it's unlikely to signal a lack of confidence from the CEO. The overall impact on share price is likely minimal given the explanation.
• Employees: No direct impact on employees, but the vesting of equity awards for the CEO reflects the company's compensation structure for executives.

Key Dates

Keywords

Adaptive Biotechnologies, ADPT, Chad M. Robins, Insider Trading, Form 4, Stock Sale, CEO, Equity Compensation, RSU Vesting, PSU Vesting, Tax Withholding